Warning: mkdir(): Permission denied in /home/virtual/lib/view_data.php on line 87 Warning: chmod() expects exactly 2 parameters, 3 given in /home/virtual/lib/view_data.php on line 88 Warning: fopen(/home/virtual/e-kjs/journal/upload/ip_log/ip_log_2025-04.txt): failed to open stream: No such file or directory in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96
|
||
Funding/Support
The Thailand Science Research and Innovation Fund (Fundamental Fund 2025, Grant No. 5025/2567) and School of Medicine, University of Phayao, Thailand.
Acknowledgments
All authors would like to thank the Thailand Science Research and Innovation Fund (Fundamental Fund 2025, Grant No. 5025/2567) and the School of Medicine, University of Phayao.
Author Contribution
Conceptualization: WL, STC, AS, WC, MHW, LCY, HJP, HJL; Data curation: WL, STC, AS, WC, MHW, LCY, HJP, HJL; Formal analysis: WL, WC; Methodology: WL, WC, MHW, LCY, HJP, HJL; Project administration: WL; Visualization: WL, STC, AS, WC, MHW, LCY, HJP, HJL; Writing – original draft: WL; Writing – review & editing: WL.
No. | Study | Published year | Nationality | Type of study | Sample size (n) | Age (yr) | Female (%) | Male (%) | Symptom duration (wk) | Level of disc herniation | Previous conservative treatment (%) | Conservative treatment duration (wk) | Physical occupation (%) | Neurological deficits |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Ruetten et al. [5] | 2008 | Germany | Prospective, randomized, controlled | 175 | 27–62 (mean, 43) | 66 | 34 | 5 Days to 8 months (mean, 94 days) | C2–C3–C7–T1 | 85 | 10 | NM | Intolerable radicular pain or neurologic deficits |
2 | Kim et al. [6] | 2009 | South Korea | Prospective | 3 | 42, 46, 50 | 0 | 100 | 2 to 2 yr | C6–7 | NM | NM | 100 (all soldiers) | Triceps weakness, radicular pain, neck pain |
3 | Yang et al. [10] | 2014 | China | Retrospective comparative cohort | 84 | AFECD: 41.3 (28–57), PFECD: 40.5 (32–68) | AFECD: 38, PFECD: 33 | Not provided | AFECD: 6–46, PFECD: 2–48 | C3–4, C4–5, C5–6, C6–7 | Not explicitly mentioned | Minimum 4 | NM | Radiculopathy and/or myelopathy |
4 | Ye et al. [11] | 2017 | China | Clinical observation | 9 | 39–56 (mean, 46) | 33 | 66 | 2–26 (mean, 16) | C4–7 | 77 | 12 | NM | Intolerable radicular pain or neurologic deficits |
5 | Zheng et al. [12] | 2018 | China | Retrospective review of PECD cases | 252 | NM | 129/252 (51) | 120/252 (48) | NM | C3–4, C4–5, C5–6, C6–7 | 100 | 12 | NM | Radicular pain, single-level foraminal soft disc herniation or foraminal stenosis |
6 | Wan et al. [13] | 2018 | China | Prospective, clinical study | 25 | 27–57 (mean, 38) | 44 | 56 | 2 to 10 Mo (mean, 5.5) | C4–5, C5–6, C6–7, C7–T1 | NM | > 6 | NM | Arm/shoulder radicular pain, upper-extremity numbness, muscle weakness, weakened tendon reflex |
7 | Lee et al. [14] | 2018 | South Korea | Retrospective review | 106 | Mean: 49.2 (SD, 10.8) | 35.9 | 64.1 | Median: 2.3 mo | C5–6 | NM | NM | NM | Motor weakness in 72% of patients |
8 | Yu et al. [15] | 2019 | China | Retrospective observational study | 30 | 47.7 ± 12.5 (26–79) | 43.8 | 56.2 | Mean 19.5 mo | C3–4, C4–5, C5–6, C6–7 | NM | At least 4 | NM | Radiculopathy, myelopathy (Nurick grade ≤ 3) |
9 | Xiao et al. [16] | 2019 | China | Retrospective comparative study | 84 | 52.9 ± 14.3 (group A), 55.4 ± 12.3 (group B) | Group A (22) | Group A (18) | 11.2±5.6 mo (group A), 10.8 ± 5.8 mo (group B) | C4–5, C5–6, C6–7 | NM | NM | NM | Unilateral cervical radiculopathy with arm pain or loss of sensory/motor function |
Group A: posterior percutaneous endoscopic cervical discectomy (P–PECD) | Group B (24) | Group B (20) | ||||||||||||
Group B: P–PECD combined with partial pediculectomy | ||||||||||||||
10 | Shu et al. [17] | 2019 | China | Retrospective study | 32 | Mean: 63.0 ± 10.5 | 56.25 | 43.75 | At least 12 | C4–5, C5–6, C6–7 | All patients | Not specified | NM | Radicular pain with foraminal stenosis |
11 | Tong et al. [18] | 2020 | China | Retrospective cohort study | 46 | 54.22 ± 10.52 (VBD)/57.48 ± 7.80 (SDD) | 47.8 (VBD) | 52.2 (VBD) | 3 Mo (minimum) | C5–6, C6–7 | 100 (ineffective conservative treatment for 3 months) | NM | NM | Unilateral root symptoms (pain, numbness, weakness) |
12 | Yuan et al. [19] | 2020 | China | Comparative study (prospective) | 46 | 42.41 ± 7.06 (spinal endoscopy group), 46.04 ± 8.85 (ACDF group) | 36.4 (spinal endoscopy), 25 (ACDF) | 63.6 (spinal endoscopy), 75 (ACDF) | Not explicitly mentioned | Single or 2-level compressive lesions | NM | NM | NM | Upper and lower limb motor dysfunction, sensory dysfunction |
13 | Carr et al. [20] | 2020 | USA | Prospective study of cervical stenosis | 10 | 70.2 ± 5.0 | 60 | 40 | NM | C3–4 | NM | NM | NM | Severe cervical myelopathy (CSM) |
14 | Ji-jun et al. [21] | 2020 | China | Prospective cohort study | 81 | ACDF: 51.4 ± 8.2, PECD: 46.6 ± 8.8 | 28 (PECD), 11 (ACDF) | 27 (PECD), 15 (ACDF) | NM | C3–4, C4–5, C5–6, C6–7 | Failed conservative treatment > 3 mo | NM | NM | Radicular pain, sensory/motor loss |
15 | Haijun et al. [22] | 2020 | China | Retrospective | 106 | Mean ~61 (± 2.35–2.56) | ~50 | ~50 | ~9 Mo | C4–C5, C5–C6, C6–C7 | Not explicitly mentioned | NM | NM | Arm pain, sensory impairment, or motor function loss |
16 | Wang et al. [23] | 2021 | China | Retrospective cohort control study | 74 | 44.23 ± 8.02 (T-EMG), 46.92 ± 9.72 (IOM) | ~33 (T-EMG), ~41 (IOM) | ~67 (T-EMG), ~59 (IOM) | Not explicitly mentioned | C4–5, C5–6, C6–7 | NM | NM | NM | CSR, radiculopathy with arm pain and numbness |
17 | Tacconi et al. [24] | 2021 | Italy | Randomized study | 37 | 30–80 (median, 50) | 51 | 49 | > 6 | C4–C5, C5–C6, C6–C7 | NM | > 6 | NM | Unilateral radiculopathy due to foraminal stenosis |
18 | Yu et al. [25] | 2021 | China | Retrospective comparative cohort | 28 | 24–81 (mean, 40) | 33 (3.7 mm) 50 (6.9 mm) | Not specified | 7–48 (mean 14 for 3.7 mm, 16 for 6.9 mm) | C4–C5, C5–C6, C6–C7, C7–T1 | Not explicitly mentioned | Not explicitly mentioned | NM | Unilateral cervical spondylotic radiculopathy with radiating pain |
19 | Ran et al. [26] | 2021 | China | Prospective cohort study | 21 | 37–66 (mean, 49.9) | ~57 | ~43 | 0.3–60 Mo (mean, 10.4 mo) | Single-level CSM | NM | NM | NM | Intolerable pain, CSM confirmed by MRI and CT |
20 | Liu et al. [27] | 2021 | China | Retrospective, single-center study | 87 | Mean: 52.1 | 49 | 38 | NM | C4–5, C5–6, C6–7, C7–T1 | NM | > 12 | NM | Numbness, radicular pain, some motor dysfunction |
21 | Wu et al. [28] | 2021 | South Korea | Prospective, retrospective analysis | 25 | Mean 51.8 ± 8.9 | 36 | 64 | NM | C5–6, C6–7 | NM | > 6 | NM | NM |
22 | Ma et al. [29] | 2022 | China | Retrospective study | 127 | 44.5 ± 11.2 (ACDF), 46.5 ± 11.3 (PECF) | ~31 (ACDF), ~32 (PECF) | ~69 (ACDF), ~68 (PECF) | 25.3 ± 8.9 (PECF), 27.3 ± 9.2 (ACDF) | C3–4, C4–5, C5–6, C6–7 | Failed conservative treatment | At least 12 | NM | Radiculopathy with single-level cervical herniation |
23 | Gatam et al. [30] | 2022 | Indonesia | Prospective, single-arm study | 65 | 33–78 (mean, 45.6) | ~48 | ~52 | > 12 | C4–5, C5–6, C6–7 | 100 | > 12 | NM | Radicular arm pain |
24 | Zhong et al. [31] | 2022 | China | Retrospective | 34 | 54.75 ± 9.74 | ~56 | ~44 | 6.12 ± 2.36 Mo | C4–5, C5–6, C6–7 | NM | NM | NM | Severe unilateral upper limb pain |
25 | Kang et al. [32] | 2022 | Korea | Retrospective review | 65 | 53.74 ± 8.50 (PE), 52.68 ± 9.56 (BE) | Not specified | Not specified | > 6 conservative treatment | Single-level, unilateral foraminal disc disease | 100 | > 6 | NM | Cervical radiculopathy |
26 | Dalgic et al. [33] | 2022 | Turkey | Retrospective case series | 83 | 30–70 (MD group: 51.1, EAD group: 38.7) | 52.3 (MD), 63.4 (EAD) | 47.7 (MD), 37.6 (EAD) | NM | C3–C4, C4–C5, C5–C6, C6–C7, C7–T1 | NM | Minimum of 4 | NM | 61.9 (MD), 48.8 (EAD) |
27 | Shi et al. [34] | 2023 | China | Retrospective study | 22 | 49.6 ± 9.2 (range 36–78) | 7 (32) | 15 (68) | Not specified | C3–4, C4–5, C5–6, C6–7 | Failed conservative treatment | 6 | NM | Radicular symptoms due to foraminal bony stenosis |
28 | Kotheeranurak et al. [35] | 2024 | Thailand | Retrospective matched-pair comparison study | 60 | 38 ± 6.43 (CDR), 38 ± 3.23 (PECD) | 63 (CDR), 57 (PECD) | 37 (CDR), 43 (PECD) | NM | Unilateral cervical disc herniation | NM | NM | NM | Radicular pain, motor or sensory deficits |
29 | Li et al. [36] | 2024 | China | Retrospective, propensity score-matched | 138 (62 Endoscopic, 76 ACDF) | 63.44 ± 8.38 (endoscopic), 66.47 ± 8.59 (ACDF) | 45.2 (endoscopic), 44.7 (ACDF) | 54.8 (endoscopic), 55.3 (ACDF) | Disease duration: 20.98 ± 8.27 mo (endoscopic), 24.51 ± 7.72 mo (ACDF) | C3–7 | Not explicitly mentioned | Not provided | NM | Myelopathy, myeloradiculopathy, Radiculopathy |
30 | Lee et al. [37] | 2024 | Japan | Retrospective case series | 25 | Mean 57 (21–76) | 8 | 92 | Mean 10 mo (1–119 mo) | C4–5, C5–6 | Conservative treatment for ≥1 mo | 1 to 6 mo | NM | Cervical spondylotic amyotrophy (CSA), muscle atrophy |
NM, not mentioned; AFECD, anterior full endoscopic cervical discectomy; PFECD, Posterior Full Endoscopic Cervical Discectomy; FPCF, full percutaneous cervical foraminotomy; ACDF, anterior cervical discectomy and fusion; PECD, posterior endoscopic cervical discectomy; T-EMG, triggered electromyography; CSM, cervical spondylotic myelopathy; CSA, cervical spondylotic amyotrophy; IOM, intraoperative monitoring; PE, percutaneous endoscopic; BE, biportal endoscopic; VBD, ventral bony decompression; SDD, simple dorsal decompression; CSR, cervical spondylotic radiculopathy; MD, microdiscectomy, EAD, endoscope-assisted discectomy.
No. | Study | Sample size (n) | Arm pain relief (%) | Occasional pain (%) | Neck pain reduction (VAS) | Mean operating time (min) | Intraoperative blood loss (mL) | Mean hospital stay (day) | Postoperative work disability (day) | Complication rate (%) | Revision rate (%) | Patient satisfaction (%) | Recurrence rate (%) | Neurologic deficit improvement (%) | Postoperative dysphagia (%) | Overall clinical success (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Ruetten et al. [5] | 175 | 87.4 | 9.2 | Significant reduction | 68 (ACDF), 28 (FPCF) | < 10 (ACDF), none (FPCF) | NM | 19 (FPCF), 34 (ACDF) | 3 (FPCF) | 4.7 (ACDF), 6.7 (FPCF) | 91 (ACDF), 96 (FPCF) | 6.7 (FPCF) | Significant reduction | Transient in 3 (ACDF) | Significant improvement |
2 | Kim et al. [6] | 3 | 90 improvement in 2 patients | NM | 3-4/10 to minimal | NM | NM | NM | 10 to 2 mo | None | None | Not explicitly mentioned | None | Triceps weakness improved to motor grade V/V | NM | Excellent (MacNab criteria) |
3 | Yang et al. [10] | 84 | Not provided | Not provided | Significant improvement | AFECD: 63.5, PFECD: 78.5 | Negligible | AFECD: 4.9, PFECD: 4.5 | NM | 4.8 overall | AFECD: 1, PFECD: 1 | Not provided | 3.6 | Not explicitly provided | NM | Favorable in both groups |
4 | Ye et al. [11] | 9 | Not provided | Not provided | 7.89 preop to 1.11 postop | 80 (mean) | None observed | 2.7 (mean) | NM | None | None | 7 Excellent, 2 good | NM | 100 (all patients) | Transient in 1 patient | 100 (all patients showed improvement) |
5 | Zheng et al. [12] | 252 | 86.7 | 13.3 | Significant reduction | 89.4 (range: 60–180) | 20.3 (range: 10–800) | 1 | NM | 1 | NM | 86.7 | 1 (epidural hematoma) | Transient in 2 patients | NM | 86.7 (MacNab criteria) |
6 | Wan et al. [13] | 25 | Significant | NM | Significant reduction | 90 (75–120) | None measurable | 3 | NM | None | 4 | 96 | NM | NM | None | 96 (22 excellent, 2 good) |
7 | Lee et al. [14] | 106 | NM | NM | 5.3 to 1.4 (24 months) | NM | NM | NM | NM | 2.8 | 1 | NM | NM | Improvement in 95 patients | Transient in 2.8 patients | Not explicitly mentioned |
8 | Yu et al. [15] | 30 | NM | NM | Significant improvement | 63.6 ± 13.5 (39–100) | NM | 3.8 ± 1.5 (1–7) | NM | 3 (1 patient) | None | 29 out of 30 patients satisfied | None | Significant improvement | NM | 29 out of 30 patients had a favorable outcome |
9 | Xiao et al. [16] | 84 | NM | NM | Reduction greater in group B at 1-, 3-, 7-day postsurgery | Group A: 74.48 ± 7.08, Group B: 66.00 ± 9.62 | NM | Group A: 3.86 ± 0.85, Group B: 3.24 ± 0.83 | NM | Group A: 10.0, Group B: 4.55 | NM | NM | NM | NM | NM | No significant difference (MacNab grading) |
10 | Shu et al. [17] | 32 | NM | NM | Reduced from 5.8 ± 1.7 to 1.1 ± 0.8 at 12 months | 56 ± 41.6 | < 10 | 3.2 ± 1.3 | NM | 3.12 (1 patient, transient thumb weakness) | None | 84.4 (excellent/good outcome) | NM | NM | None | 84.4 (Odom’s criteria: excellent/good) |
11 | Tong et al. [18] | 46 | VBD: 91.29 | SDD: 60.87 | Significant reduction | 129.39 ± 9.96 (VBD)/97.65 ± 7.54 (SDD) | NM | NM | NM | 4.3 (SDD) | NM | NM | 4.3 (SDD) | NM | NM | VBD: 91.29, SDD: 60.87 |
12 | Yuan et al. [19] | 46 | NM | NM | NM | 70.23 ± 10.91 (spinal endoscopy), 92.29 ± 13.13 (ACDF) | 30.00 ± 7.30 (spinal endoscopy), 132.38 ± 14.33 (ACDF) | 4.23 ± 1.11 (spinal endoscopy), 8.21 ± 1.50 (ACDF) | NM | NM | 4.5 (spinal endoscopy), 0 (ACDF) | 81.8 (spinal endoscopy), 83.3 (ACDF) | NM | JOA improvement: 67.59 (spinal endoscopy), 69.37 (ACDF) | NM | 81.8 (spinal endoscopy), 83.3 (ACDF) |
13 | Carr et al. [20] | 10 | NM | NM | 5.8 ± 0.9 (preop), 2.9 ± 0.6 (postop) | 128 ± 18.4 | < 10 | 1.2 ± 0.2 | NM | Transient neurological deficit in 1 patient (10) | None | NM | NM | Improved mJOA scores from 11.4 ± 0.9 to 14.6 ± 1.0 | None | Significant improvement |
14 | Ji-jun et al. [21] | 81 | Not specifically mentioned | NM | Significant reduction | ACDF: 59.2 ± 10.2, PECD: 95.3 ± 13.1 | ACDF: 71.4 ± 14.2, PECD: none | ACDF: 5.5 ± 1.1, PECD: 3.8 ± 0.9 | NM | 9.3 | None | NM | NM | Significant improvement (PECD) | 10.5 (ACDF) | NM |
15 | Haijun et al. [22] | 106 | Not provided | Not provided | Significant improvement | 60.47 (delta), 75.46 (key-hole) | 20.47 (delta), 20.33 (key-hole) | 4.45–4.66 | NM | 5.35 (delta), 10 (key-hole) | NM | 96.4 (delta), 94.0 (key-hole) | 1 Recurrence (delta) | Improved | NM | Not provided |
16 | Wang et al. [23] | 74 | Not explicitly mentioned | NM | Reduced significantly in both groups (p < 0.05) | 108.29 ± 11.44 (T-EMG), 110.13 ± 12.70 (IOM) | NM | 5.66 ± 0.99 (T-EMG), 7.10 ± 1.43 (IOM) | NM | 1/35 (T-EMG), 7/39 (IOM) | NM | 91.43 (T-EMG), 89.7 (IOM) | NM | Significant improvement | NM | NM |
17 | Tacconi et al. [24] | 37 | NM | NM | FEPCF: 3.6 (mean); OPCF: 6.1 | 62 (FEPCF), 67.5 (OPCF) | < 50 cc (FEPCF), 50–120 cc (OPCF) | NM | NM | FEPCF: 24 (transient dysesthesia) | 1 case (FEPCF, ACDF revision) | Not explicitly mentioned | Not explicitly mentioned | NM | NM | Decrease in arm pain score by 3 points |
18 | Yu et al. [25] | 28 | Not explicitly mentioned | NM | Significant reduction in both groups | 76.5 (3.7)/61.5 (6.9) | Negligible for both groups | 5.1(3.7mm)/4.8 (6.9 mm) | NM | 3.7 | 0 | Excellent/good recovery for both groups | 0 | Not explicitly mentioned | NM | No significant difference in outcomes |
19 | Ran et al. [26] | 21 | Significant reduction (VAS decrease from 5.5 to 0.4) | NM | Significant reduction | 169.3 ± 49.8 | Minimal, controlled | NM | NM | 9.5 (2 patients had fair outcomes) | None | 90.5 | None | Significant improvement | None | 90.5 (good or excellent) |
20 | Liu et al. [27] | 87 | Significant | NM | From 7 to 3 (1 yr) | 74.3 | 30.1 | 4.7 | NM | None reported | NM | NM | None reported | NM | None reported | Significant improvement |
21 | Wu et al. [28] | 25 | NM | NM | Mean improvement of 5.08 ± 1.75 | 52.6 | NM | NM | NM | 12 | 0 | 92 (MacNab criteria: good and excellent results) | 4 (one case) | 2 cases of motor deficits recovered within 1 year | NM | NM |
22 | Ma et al. [29] | 127 | Not explicitly mentioned | NM | Significant reduction | 66.8 ± 6.8 (PECF), 59.4 ± 9.1 (ACDF) | NM | 3.7 ± 1.3 (PECF), 6.8 ± 1.5 (ACDF) | NM | 17.2 (ACDF), 3.4 (PECF) | NM | NM | NM | Significant improvement | 3.4 (ACDF) | NM |
23 | Gatam et al. [30] | 65 | Significant VAS reduction | NM | No neck pain | 47.8 | ~23.6 | 1.5 | NM | 6.15 hypesthesia | NM | Good to excellent results (MacNab) | NM | Fair in 5 patients (hypesthesia) | NM | Good to excellent (MacNab criteria) |
24 | Zhong et al. [31] | 34 | NM | NM | 7.25→0.25 (2 years) | 81.18 ± 10.87 | None | 4.52 ± 1.22 | NM | 0 | 0 | 91.17 (excellent+good) | 0 | NM | 0 | 91.17 (excellent+good) |
25 | Kang et al. [32] | 65 | Significant improvement | NM | VAS-arm and VAS-neck both improved | 78.61 ± 14.47 (PE), 70.97 ± 12.00 (BE) | NM | 2.16 ± 1.44 (PE), 2.48 ± 1.23 (BE) | NM | 3 (PE), 3 (BE) | 3.1 (PE), 3 (BE) | 91.7 (PE), 87.9 (BE) | NM | Significant improvement | NM | Excellent or good (PE: 91.7, BE: 87.9) |
26 | Dalgic et al. [33] | 83 | NM | NM | Preop Neck: 7.74 | 74.39 (MD), 81.4 (EAD) | 88.29 (MD), 81.5 (EAD) | NM | NM | 7.1 (MD), 7.3 (EAD) | 0 (MD), 1 (EAD) | Not explicitly mentioned | 2.4 (EAD) | Not explicitly mentioned | NM | 90.3 |
Postop Neck: 2.23 | ||||||||||||||||
27 | Shi et al. [34] | 22 | Not specified | Not specified | Preop 8.09 ± 1.24; 1 wk: 2.14 ± 1.83 | 141.6 ± 13.7 | NM | 6.0 ± 2.5 | NM | 1 case (4.5 hematoma) | NM | NM | NM | Significant improvement | NM | NM |
28 | Kotheeranurak et al. [35] | 60 | Not specifically mentioned | NM | Improved in both groups (p < 0.05) | 42.3 ± 13.1 (CDR), 48.3 ± 20.1 (PECD) | 20.1 ± 10.6 (CDR), 5.4 ± 15.2 (PECD) | 3.2 ± 2.6 (CDR), 1.2 ± 1.5 (PECD) | 12.7 ± 10.4 (CDR), 5.2 ± 8.5 (PECD) | 5 (both groups) | None | 86 rated “good” or “excellent” | NM | Significant improvement in both groups | 10 (CDR), 0 (PECD) | 87 (excellent or good) |
29 | Li et al. [36] | 138 (62 Endoscopic, 76 ACDF) | Not explicitly mentioned | NM | Significant reduction in both groups | 85.43 ± 5.16 (endoscopic), 98.48 ± 7.84 (ACDF) | 8.29 ± 2.68 (endoscopic), 50.40 ± 4.46 (ACDF) | 6.14 ± 0.87 (endoscopic), 8.07 ± 0.84 (ACDF) | NM | Neurological dysfunction: 1 (Endoscopic), 2 (ACDF); CSF leakage: 2 (endoscopic, 2 ACDF) | Revision: 0 (endoscopic), 1 (ACDF) | 90.48 (endoscopic), 88.10 (ACDF) | NM | Not explicitly mentioned | Dysphagia: 1 (ACDF) | 90.48 (endoscopic), 88.10 (ACDF) |
30 | Lee et al. [37] | 25 | NM | NM | NM | 86 (C4/5), 72 (C5/6) | NM | 2–25 (mean 4.2) | NM | Tiny epineural injury in 1 case | NM | NM | NM | Significant improvement (84) | NM | Improvement in 84 of cases |
NM, not mentioned; AFECD, anterior full endoscopic cervical discectomy; PFECD, Posterior Full Endoscopic Cervical Discectomy; FPCF, full percutaneous cervical foraminotomy; ACDF, anterior cervical discectomy and fusion; PECD, posterior endoscopic cervical discectomy; T-EMG, triggered electromyography; IOM, intraoperative monitoring; PE, percutaneous endoscopic; BE, biportal endoscopic; VBD, ventral bony decompression; SDD, simple dorsal decompression; VAS, visual analogue scale; JOA, Japanese Orthopaedic Association; mJOA, modified JOA; FEPCF, Full-endoscopic posterior cervical foraminotomy; MD, microdiscectomy, EAD, endoscope-assisted discectomy; OPCF, open posterior cervical foraminotomy; PECF, percutaneous endoscopic cervical foraminotomy; CDR, cervical disc replacement.
Study No. | Study | Confounding | Selection of participants | Classification of interventions | Deviations from intended interventions | Missing data | Measurement of outcomes | Selection of reported results | Overall |
---|---|---|---|---|---|---|---|---|---|
1 | Kim et al. [6] | Serious | Moderate | Low | Low | Low | Moderate | Low | Serious |
2 | Yang et al. [10] | Moderate | Moderate | Low | Low | Low | Moderate | Low | Moderate |
3 | Ye et al. [11] | Serious | Moderate | Low | Low | Low | Moderate | Low | Serious |
4 | Zheng et al. [12] | Moderate | Moderate | Low | Low | Low | Moderate | Low | Moderate |
5 | Wan et al. [13] | Serious | Moderate | Low | Low | Low | Moderate | Low | Serious |
6 | Lee et al. [14] | Moderate | Moderate | Low | Low | Low | Moderate | Low | Moderate |
7 | Yu et al. [15] | Moderate | Moderate | Low | Low | Low | Moderate | Low | Moderate |
8 | Xiao et al. [16] | Moderate | Moderate | Low | Low | Low | Moderate | Low | Moderate |
9 | Shu et al. [17] | Moderate | Moderate | Low | Low | Low | Moderate | Low | Moderate |
10 | Tong et al. [18] | Moderate | Moderate | Low | Low | Low | Moderate | Low | Moderate |
11 | Yuan et al. [19] | Moderate | Moderate | Low | Low | Low | Moderate | Low | Moderate |
12 | Carr et al. [20] | Moderate | Moderate | Low | Low | Low | Moderate | Low | Moderate |
13 | Ji-jun et al. [21] | Low | Low | Low | Low | Low | Low | Low | Low |
14 | Haijun et al. [22] | Moderate | Low | Low | Low | Low | Low | Low | Moderate |
15 | Wang et al. [23] | Low | Low | Low | Low | Low | Low | Low | Low |
16 | Yu et al. [25] | Moderate | Moderate | Low | Low | Low | Moderate | Low | Moderate |
17 | Ran et al. [26] | Moderate | Moderate | Low | Low | Low | Moderate | Low | Moderate |
18 | Liu et al. [27] | Moderate | Low | Low | Low | Moderate | Moderate | Low | Moderate |
19 | Wu et al. [28] | Moderate | Low | Low | Low | Low | Low | Low | Moderate |
20 | Ma et al. [29] | Moderate | Low | Low | Low | Low | Low | Low | Moderate |
21 | Gatam et al. [30] | Low | Low | Low | Low | Low | Low | Low | Low |
22 | Zhong et al. [31] | Moderate | Low | Low | Low | Low | Low | Low | Moderate |
23 | Kang et al. [32] | Moderate | Low | Low | Low | Low | Low | Low | Moderate |
24 | Dalgic et al. [33] | Low | Low | Low | Low | Low | Low | Low | Low |
25 | Shi et al. [34] | Moderate | Low | Low | Low | Low | Low | Low | Moderate |
26 | Kotheeranurak et al. [35] | Moderate | Low | Low | Low | Low | Low | Low | Moderate |
27 | Li et al. [36] | Low | Low | Low | Low | Low | Low | Low | Low |
28 | Lee et al. [37] | Low | Low | Low | Low | Low | Low | Low | Low |
Study | Randomization | Deviation from the intended intervention | Missing outcome data | Measurement of the outcome | Selection of the report results | Overall |
---|---|---|---|---|---|---|
Ruetten et al. [5] | Low | Low | Low | Low | Low | Low |
Tacconi et al. [24] | Low | Low | Low | Low | Low | Low |
Spinal Robotics in Adult Spinal Deformity Surgery: A Systematic Review2024 March;21(1)